Articles related to Urology

Perioperative apalutamide plus ADT, six months before and after radical prostatectomy, achieved a ninefold improvement in major pathologic response and a 20% reduction in metastasis-free survival events versus placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer in a phase 3 trial.

Talazoparib plus enzalutamide reduced the risk of radiographic progression or death by 52% versus enzalutamide alone in patients with metastatic castration-sensitive prostate cancer harboring homologous recombination repair gene alterations, with a 3-year rPFS rate of 77% versus 56% in a 599-patient phase 3 trial.

A two-sample analysis of GWAS data identified genetically predicted associations between six commonly prescribed medications and increased erectile dysfunction risk, while aspirin did not reach statistical significance after SNP exclusions.

Neoadjuvant apalutamide plus abiraterone and ADT before radical prostatectomy was associated with improved 12-month potency recovery and lower positive surgical margin rates compared with surgery alone in a small phase 2 trial of men with high-risk localized prostate cancer.

Cotrimoxazole was associated with nearly twice the adverse event rate of fluoroquinolones in a retrospective study of 228 hospitalized men aged 75 or older with urinary tract infections, with acute kidney injury onset occurring at a median of six days post-initiation.

A community oncologist previewed four ASCO 2026 late-breaking abstracts spanning pancreatic, prostate, lung, and sarcoma, flagging molecular testing infrastructure and toxicity coordination as key implementation questions ahead of the data readout.